Genprex (GNPX) Prices 7.62M Share Common Offering at $1.05/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500, Nasdaq set for higher open as oil prices extend declines, midterm results awaited
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- Goldman data shows hedge funds cut leverage at fastest pace since March
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
Genprex (GNPX) Adds to Tuesday's Big Gains on FDA News; Shares Up 60%
January 22, 2020 8:33 AM ESTGenprex (NASDAQ: GNPX) adds to Tuesday gains after the company received DA Fast Track designation for its gene therapy that targets lung cancer. Shares are up 64% pre-open after gaining 219% on Tuesday.
... MoreGenprex (GNPX) Granted FDA Fast Track Designation for Gene Therapy that Targets Lung Cancer
January 21, 2020 8:01 AM ESTGenprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor... More



